Drug intelligence / Profile preview

LPH-101

Development stage: Preclinical
Lead developer: Lophora
Modality: Small Molecules
Administration: Oral

Overview

LPH-101 is a next-generation, selective small-molecule agonist of the serotonin 5-HT2A receptor (5-HT2AR) under development by Lophora. The compound is being investigated for undisclosed central nervous system (CNS) opportunities. Built on Lophora's drug design platform, which focuses on rational engineering of 5-HT2A agonists with optimized drug-like properties and reduced off-target activity, LPH-101 is currently in preclinical development.

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)

Beyond the preview

Go deeper on LPH-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPH-101.

Explore the full profile